Nuwellis, Inc. (NUWE)

NASDAQ: NUWE · IEX Real-Time Price · USD
0.698
+0.087 (14.24%)
At close: Feb 26, 2024, 3:59 PM
0.710
+0.012 (1.72%)
After-hours: Feb 26, 2024, 7:59 PM EST
14.24%
Market Cap 3.97M
Revenue (ttm) 8.65M
Net Income (ttm) -16.60M
Shares Out 5.68M
EPS (ttm) 25.23
PE Ratio 0.03
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,697,429
Open 0.660
Previous Close 0.611
Day's Range 0.640 - 0.770
52-Week Range 0.390 - 8.480
Beta 0.12
Analysts Hold
Price Target n/a
Earnings Date Mar 5, 2024

About NUWE

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1999
Employees 70
Stock Exchange NASDAQ
Ticker Symbol NUWE
Full Company Profile

Financial Performance

In 2022, Nuwellis's revenue was $8.54 million, an increase of 7.85% compared to the previous year's $7.92 million. Losses were -$14.53 million, -25.72% less than in 2021.

Financial Statements

News

Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribu...

4 days ago - GlobeNewsWire

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company's independent directors approved equity awards under Nuwelli...

6 days ago - GlobeNewsWire

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system

6 days ago - GlobeNewsWire

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics Early findings suggest Aquadex as a poten...

20 days ago - GlobeNewsWire

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultra...

7 weeks ago - GlobeNewsWire

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial r...

3 months ago - GlobeNewsWire

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its thi...

4 months ago - GlobeNewsWire

Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, ...

4 months ago - GlobeNewsWire

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, ...

4 months ago - GlobeNewsWire

Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

MINNEAPOLIS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced...

4 months ago - GlobeNewsWire

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that Pres...

6 months ago - GlobeNewsWire

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial r...

7 months ago - GlobeNewsWire

Nuwellis Announces Plan for CFO Transition

MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, announced today that Lynn ...

7 months ago - GlobeNewsWire

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its sec...

7 months ago - GlobeNewsWire

Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor ...

9 months ago - GlobeNewsWire

Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced ...

9 months ago - GlobeNewsWire

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial resu...

10 months ago - GlobeNewsWire

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-re...

1 year ago - GlobeNewsWire

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth

1 year ago - GlobeNewsWire

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor ...

1 year ago - GlobeNewsWire

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fou...

1 year ago - GlobeNewsWire

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload...

1 year ago - GlobeNewsWire

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overloa...

1 year ago - GlobeNewsWire

Nuwellis, Inc. Announces Passage of Warrant Proposal

MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Com...

1 year ago - GlobeNewsWire

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical's Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)

Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (...

1 year ago - GlobeNewsWire